Cox and National Disability Insurance Agency [2022] AATA 3911 (2 November 2022)
Division: NATIONAL DISABILITY INSURANCE SCHEME DIVISION
File Number(s): 2021/1014
Re: Glenn Cox
APPLICANT
And National Disability Insurance Agency
RESPONDENT
DECISION
Tribunal: Senior Member P Goward
Date: 2 November 2022
Place: Sydney
The Tribunal affirms the decision under review pursuant to paragraph 43(1)(a) of the
Administrative Appeals Tribunal Act 1975 (Cth).
................................[SGD]........................................
Senior Member P Goward
NATIONAL DISABILITY INSURANCE SCHEME (NDIS) – quadriplegia – whether support is reasonable and necessary – whether the NDIA should fund Botox treatment as a reasonable and necessary support –whether funding for support is consistent with relevant law and policy – whether functionality is incidental to pain management – decision under review affirmed.
LEGISLATION
Administrative Appeals Tribunal Act 1975 (Cth) – s 73
National Disability Insurance Scheme Act 2013 (Cth) – ss 3, 4, 33 – 35, 100 & 103 National Disability Insurance Scheme (Support for Participants) Rules 2013 (Cth)
CASES
McGarrigle v National Disability Insurance Agency [2017] FCA 308 National Disability Insurance Agency v WRMF [2020] FCAFC 79
Re Drake and Minister for Immigration and Ethnic Affairs (No. 2) (1979) 2 ALD 634 WRMF and National Disability Insurance Agency [2019] AATA 1771
Young and National Disability Insurance Agency [2014] AATA 401
SECONDARY MATERIALS
National Disability Insurance Scheme – Operational Guidelines – Mainstream and Community Supports
National Disability Insurance Scheme – Operational Guidelines – Planning Oxford English Dictionary
REASONS FOR DECISION
Senior Member P Goward 2 November 2022
Introduction
1.The Applicant, Mr Glenn Cox, was involved in a catastrophic car accident in 2019 and as a result is a ventilated quadriplegic. He gained access to the National Disability Insurance Scheme (NDIS) in July 2020. The Applicant subsequently applied for an internal review under section 100 of the National Disability Insurance Scheme Act 2013 (Cth) (NDIS Act or the Act), of the plan approved in July 2020.
2.Following that internal review, the National Disability Insurance Agency (NDIA), agreed to fund some, but not all, of the requested supports. The Applicant was advised on 4 December 2020 that the requested support of an increase in the Applicant’s capacity building supports for Botox therapy, the support at issue in this decision, was not considered to be a reasonable and necessary support and therefore would not be funded. Mr Cox’s current plan is due to expire in December 2022.
3.The Applicant applied to the Administrative Appeals Tribunal (the AAT or Tribunal) for review of the internal review decision on 24 February 2021.
Issue
4.The Tribunal must decide whether the provision of Botox therapy to provide pain relief is a reasonable and necessary support under the NDIS Act.
Background
5.As a result of the Applicant’s quadriplegia, three metal rods were inserted into his spinal cord to provide him with greater physical stability. Unfortunately, there is also significant spasticity and pain associated with that improvement and Mr Cox has relied on prescribed opiates to address the pain across his shoulder blades. His…
Keep reading for free
Create a free CaseChat account to read Cox and National Disability Insurance Agency and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2022] AATA 3911
- Decision Date
CaseChat Overview and Summary
The Tribunal was required to determine two primary legal issues: first, whether the proposed Botox treatment for Mr. Cox's spasticity and associated pain was a reasonable and necessary support within the meaning of the *National Disability Insurance Scheme Act 2013* (Cth); and second, whether the NDIA's decision to refuse funding for this support was consistent with the relevant provisions of the Act and associated policy. The Tribunal also had to consider whether any functional improvements derived from the treatment were incidental to its primary purpose of pain management.
In reaching its decision, the Tribunal applied the criteria for "reasonable and necessary" supports as set out in section 34 of the Act. It found that while the Botox treatment might offer some incidental functional benefits, its primary purpose and likely outcome was pain management. The Tribunal concluded that the evidence did not establish that the pain experienced by Mr. Cox was of a severity or nature that would justify funding the Botox treatment as a reasonable and necessary support under the NDIS, particularly when considering alternative pain management strategies. Consequently, the Tribunal affirmed the NDIA's decision.
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi